Conv. Plasma
Nigella Sativa

All HCQ studies
Meta analysis
study COVID-19 treatment researchHCQHCQ (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   
0 0.5 1 1.5 2+ Mortality 33% Improvement Relative Risk Death/ICU 39% Death/ICU (b) 69% HCQ for COVID-19  Lano et al.  LATE TREATMENT Is late treatment with HCQ beneficial for COVID-19? Retrospective 122 patients in France Lower mortality (p=0.28) and death/ICU (p=0.23), not sig. Lano et al., Clinical Kidney J., Octob.., Oct 2020 Favors HCQ Favors control

Risk factors for severity of COVID-19 in chronic dialysis patients from a multicentre French cohort

Lano et al., Clinical Kidney Journal, 13:5, October 2020, 878–888, doi:10.1093/ckj/sfaa199
Oct 2020  
  Source   PDF   All   Meta
HCQ for COVID-19
1st treatment shown to reduce risk in March 2020
*, now known with p < 0.00000000001 from 422 studies, recognized in 42 countries.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
4,000+ studies for 60+ treatments.
33% lower mortality with HCQ+AZ, p=0.28. Retrospective 122 French dialysis patients.
69% lower combined mortality/ICU, p=0.11, for the subgroup not requiring O2 on diagnosis (slightly earlier treatment).
Although the 33% lower mortality is not statistically significant, it is consistent with the significant 25% lower mortality [20‑29%] from meta analysis of the 250 mortality results to date.
risk of death, 33.1% lower, RR 0.67, p = 0.28, treatment 56, control 66, adjusted per study, odds ratio converted to relative risk.
risk of death/ICU, 38.9% lower, RR 0.61, p = 0.23, treatment 17 of 56 (30.4%), control 28 of 66 (42.4%), NNT 8.3, adjusted per study, odds ratio converted to relative risk.
risk of death/ICU, 68.7% lower, RR 0.31, p = 0.11, treatment 4 of 36 (11.1%), control 11 of 31 (35.5%), NNT 4.1, not requiring O2 on diagnosis (relatively early treatment).
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Lano et al., 21 Oct 2020, retrospective, France, peer-reviewed, median age 73.5, 30 authors.
This PaperHCQAll
Risk factors for severity of COVID-19 in chronic dialysis patients from a multicentre French cohort
Guillaume Lano, Antoine Braconnier, Stanislas Bataille, Guilhem Cavaille, Julie Moussi-Frances, Bertrand Gondouin, Pascal Bindi, Magued Nakhla, Janette Mansour, Pascale Halin, Bénédicte Levy, Eric Canivet, Khaled Gaha, Isabelle Kazes, Natacha Noel, Alain Wynckel, Alexandre Debrumetz, Noemie Jourde-Chiche, Valerie Moal, Romain Vial, Violaine Scarfoglière, Mickael Bobot, Marion Gully, Tristan Legris, Marion Pelletier, Marion Sallee, Stephane Burtey, Philippe Brunet, Thomas Robert, Philippe Rieu
Clinical Kidney Journal, doi:10.1093/ckj/sfaa199
Background. Coronavirus disease 2019 (COVID-19) is an emerging infectious disease, related to severe acute respiratory syndrome coronavirus 2 infection. Few data are available in patients with end-stage renal disease (ESRD). Methods. We conducted an observational cohort study of COVID-19 patients at 11 dialysis centres in two distinct districts of France to examine the epidemiological and clinical characteristics of COVID-19 in this population, and to determine risk factors of disease severity (defined as a composite outcome including intensive care unit admission or death) and mortality. Results. Among the 2336 patients enrolled, 5.5% had confirmed COVID-19 diagnosis. Of the 122 patients with a follow-up superior to 28 days, 37% reached the composite outcome and 28% died. Multivariate analysis showed that oxygen therapy on diagnosis and a decrease in lymphocyte count were independent risk factors associated with disease severity and with mortality. Chronic use of angiotensin II receptor blockers (ARBs) (18% of patients) was associated with a protective effect on mortality. Treatment with azithromycin and hydroxychloroquine (AZT/HCQ) (46% of patients) were not associated with the composite outcome and with death in univariate and multivariate analyses. Conclusions. COVID-19 is a severe disease with poor prognosis in patients with ESRD. Usual treatment with ARBs seems to be protective of critical evolution and mortality. There is no evidence of clinical benefit with the combination of AZT/HCQ.
SUPPLEMENTARY DATA Supplementary data are available at ckj online. AUTHORS' CONTRIBUTIONS G.L., A.B., T.R. and P.R. conceived and designed the study, and drafted the manuscript. S.Bataille, G.C., J.M.-F., B.G., P.Bindi, M.N., J.M., P.H., B.L., E.C., K.G., I.K., N.N., A.W., A.D., N.J.-C., V.M., R.V., V.S., M.B., M.G., T.L., M.P., M.S., S.Burtey and P.Brunet were involved in data collection analysis and provided guidance. All authors critically revised the manuscript for important intellectual content and approved the final version for publication. CONFLICT OF INTEREST STATEMENT All the authors declare that they have no conflict of interest.
Alberici, Delbarba, Manenti, A report from the Brescia renal COVID task force on the clinical characteristics and short-term outcome of hemodialysis patients with SARS-CoV-2 infection, Kidney Int
Alhenc-Gelas, Drueke, Blockade of SARS-CoV-2 infection by recombinant soluble ACE2, Kidney Int
Arslan H, Musabak, Soy, Incidence and immunologic analysis of coronavirus disease (COVID-19) in hemodialysis patients: a single-center experience, Exp Clin Transplant
Basile, Combe, Pizzarelli, Recommendations for the prevention, mitigation and containment of the emerging SARS-CoV-2 (COVID-19) pandemic in haemodialysis centres, Nephrol Dial Transplant
Bataille, Pedinielli, Bergounioux, Could ferritin help the screening for COVID-19 in hemodialysis patients?, Kidney Int
Fosbøl, Butt, Østergaard, Association of angiotensin-converting enzyme inhibitor or angiotensin receptor blocker use with COVID-19 diagnosis and mortality, JAMA
Gautret, Lagier, Parola, Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: a pilot observational study, Travel Med Infect Dis
Goicoechea, Sa ´nchez Ca ´mara, COVID-19: clinical course and outcomes of 36 maintenance hemodialysis patients from a single center in Spain, Kidney Int
Grasselli, Zangrillo, Zanella, for the COVID-19 Lombardy ICU Network. Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy Region, Italy, JAMA
Henry, Lippi, Chronic kidney disease is associated with severe coronavirus disease 2019 (COVID-19) infection, Int Urol Nephrol
Hoffmann, Kleine-Weber, Schroeder, SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor, Cell
Huang, Wang, Li, Clinical features of patients infected with 2019 novel coronavirus in Wuhan China, Lancet
Mackey, King, Gurley, Risks and impact of angiotensin-converting enzyme inhibitors or angiotensinreceptor blockers on SARS-CoV-2 infection in adults: a living systematic review, Ann Int Med
Mancia, Rea, Ludergnani, Renin-angiotensin-aldosterone system blockers and the risk of covid-19, N Engl J Med
Marco, Puchades, Romero-Parra, Coronavirus disease 2019 in chronic kidney disease, Clin Kidney J
Michaud, Deodhar, Arwood, ACE2 as a therapeutic target for COVID-19; its role in infectious processes and regulation by modulators of the RAAS system, J Clin Med
Milia, Bacchini, Bigi, COVID-19 outbreak in a large hemodialysis center in Lombardy, Italy, Kidney Int Rep
Salje, Kiem, Lefrancq, Estimating the burden of SARS-CoV-2 in France, Science
Sparks, South, Welling, Sound science before quick judgement regarding RAS blockade in COVID-19, Clin J Am Soc Nephrol
Stock Da Cunha, Goma, ´s, Avello, The spectrum of clinical and serological features of COVID-19 in urban hemodialysis patients, J Clin Med
Wang, He, Liao, Clinical outcomes of hemodialysis patients infected with severe acute respiratory syndrome coronavirus 2 and impact of proactive chest computed tomography scans, Clin Kidney J
Wiersinga, Rhodes, Cheng, Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): a review, JAMA
Wu, Chen, Cai, Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 Pneumonia in Wuhan, China, JAMA Int Med
Xiong, Tang, Liu, Clinical characteristics of and medical interventions for COVID-19 in hemodialysis patients in Wuhan, China, J Am Soc Nephrol
Yau, Muller, Lin, COVID-19 outbreak in an urban hemodialysis unit, Am J Kidney Dis, doi:10.1053/j.ajkd.2020.07.001
Zhang, Penninger, Li, Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target, Intensive Care Med
Zhang, Yu, Pan, ACEI/ARB use and risk of infection or severity or mortality of COVID-19: a systematic review and meta-analysis, Pharmacol Res
Zhang, Zhu, Cai, Association of inpatient use of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers with mortality among patients with hypertension hospitalized with COVID-19, Circ Res
Zhao, Meng, Kumar, Lymphopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: a systemic review and meta-analysis, Int J Infect Dis
Zheng, Peng, Xu, Risk factors of critical & mortal COVID-19 cases: a systematic literature review and metaanalysis, J Infect
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop